In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Antidepressant Use in Meningioma: Association with Tumor Recurrence during Long-term Follow-up

    Final Number:
    1135

    Authors:
    Joshua Loewenstern; Karan Kohli; Remi Aria Kessler; Margaret Pain MD; Christina Palmese PhD; Joshua B. Bederson MD; Raj K Shrivastava MD

    Study Design:
    Laboratory Investigation

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2018 Annual Meeting

    Introduction: With increasing use of antidepressants (AD) among neurosurgical patients, multiple studies have noted a small protective effect of AD for glioma patients, but their impact on meningiomas has not been established. The study aims to evaluate the role of AD in the context of additional clinical factors in relation to long-term risk of meningioma recurrence.

    Methods: 105 patients with an intracranial meningioma presenting from 2011-2014 with at least 3 years of follow-up (median=4.2 years) post-resection were reviewed. AD use along with demographics, tumor characteristics, and outcomes were recorded. Multivariate logistic regression analyzed AD use on tumor recurrence, including other clinical measures significantly associated with recurrence as covariates.

    Results: Twenty-nine patients (27.4%) were taking AD (27 SSRIs, 2 NDRIs) prior to tumor recurrence. Their tumors largely affected the frontal (31.0%) or parietal lobe (17.2%) and were located in convexity, parasagittal, or falcine (CPF) areas more frequently than skull base areas relative to non-AD users (p=0.035, Figure 1). AD use was found to be an independent predictor of recurrence, in addition to subtotal resection and WHO grade II/III classification (p’s<0.05). Median time from AD prescription to recurrence was 36.6 months (IQR=20.9-62.9) and median length of use was 41.4 months (IQR=24.7-62.8).

    Conclusions: AD use was an independent predictor of meningioma recurrence. The association may be due to mood or affective changes caused by tumor location in CPF regions that may be a sign of early recurrence. The finding calls attention to AD use in the management of meningioma patients, and warrants further exploration of an underlying relationship.

    Patient Care: The present study provides evidence for the potential relationship among meningioma location, grade, and mood dysfunction in predicting risk for tumor recurrence.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Understand the patterns of antidepressant use among meningioma patients and their potential correlation with tumor progression 2) Describe the relationship among meningioma location and grade with antidepressant use during long-term follow-up 3) Identify a possible role of antidepressant use in predicting patients who are at higher risk for a tumor recurrence

    References: 1. Liu KH, Yang ST, Lin YK, et al. Fluoxetine, an antidepressant, suppresses glioblastoma by evoking AMPAR-mediated calcium-dependent apoptosis. Oncotarget. 2015;6(7):5088. 2. Cea-Soriano L, Wallander MA, Garcia Rodriguez LA. Epidemiology of meningioma in the United Kingdom. Neuroepidemiology. 2012;39(1):27-34.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy